Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Martin Maenz"'
Autor:
Matthias P Ebert, ProfMD, Nadja M Meindl-Beinker, PhD, Tobias Gutting, MD, Martin Maenz, PhD, Johannes Betge, MD, Nadine Schulte, MD, Tianzuo Zhan, MD, Philip Weidner, MD, Elke Burgermeister, PhD, Ralf Hofheinz, ProfMD, Arndt Vogel, ProfMD, Stefan Angermeier, MD, Claus Bolling, MD, Maike de Wit, ProfMD, Ralf Jakobs, ProfMD, Meinolf Karthaus, ProfMD, Gertraud Stocker, MD, Peter Thuss-Patience, MD, Tobias Leidig, PhD, Timo Gaiser, ProfMD, Jakob N Kather, ProfMD, Nicolai Haertel, MD
Publikováno v:
The Lancet. Healthy Longevity, Vol 3, Iss 6, Pp e417-e427 (2022)
Summary: Background: The overall survival of patients with advanced and refractory oesophageal squamous cell carcinoma, mostly aged 65 years and older, is poor. Treatment with PD-1 antibodies showed improved progression-free survival and overall surv
Externí odkaz:
https://doaj.org/article/44c5e9f98cad4d8cb78f0b4c9de02298
Autor:
Jonas Kuon, Adriane Hommertgen, Johannes Krisam, Felix Lasitschka, Albrecht Stenzinger, Miriam Blasi, Farastuk Bozorgmehr, Martin Maenz, Meinhard Kieser, Marc Schneider, Michael Thomas
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-12 (2020)
Abstract Background Elderly patients represent a major fraction of non-small cell lung cancer (NSCLC) patients in routine clinical practice, but they are still underrepresented in clinical trials. In particular, data regarding efficacy and safety in
Externí odkaz:
https://doaj.org/article/1ae670ccfeb143f6862080ce2e23e2f0
Autor:
Farastuk Bozorgmehr, Adriane Hommertgen, Johannes Krisam, Felix Lasitschka, Jonas Kuon, Martin Maenz, Peter E. Huber, Laila König, Meinhard Kieser, Juergen Debus, Michael Thomas, Stefan Rieken
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background Hypofractionated palliative radiotherapy for metastatic lung cancer patients is frequently used in order to ease pain, to increase bone stability, to treat local mass effects, or to prolong progression-free survival at critical si
Externí odkaz:
https://doaj.org/article/f3816410675a4a808561538a82901dbe
Autor:
Nadja M. Meindl-Beinker, Johannes Betge, Tobias Gutting, Elke Burgermeister, Sebastian Belle, Tianzuo Zhan, Nadine Schulte, Martin Maenz, Matthias P. Ebert, Nicolai Haertel
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background Advanced esophageal squamous cell cancer (ESCC) is frequently diagnosed in elderly patients. The impact of 2nd line chemotherapy is poorly defined. Recent data demonstrated effectiveness of checkpoint inhibitors in different squam
Externí odkaz:
https://doaj.org/article/213aab5f04994d7d828225467c3dd8b1
Autor:
Johannes Betge, Jing Chi-Kern, Nadine Schulte, Sebastian Belle, Tobias Gutting, Elke Burgermeister, Ralf Jesenofsky, Martin Maenz, Ulrich Wedding, Matthias P. Ebert, Nicolai Haertel
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background In the group of elderly patients (≥70 years) with metastatic pancreatic ductal adenocarcinoma (mPDAC), it is not known who benefits from intensive 1st line nab-paclitaxel/gemcitabine (nab-p/gem) combination chemotherapy or who w
Externí odkaz:
https://doaj.org/article/1b0752c83e964285a87408a0460a531c
Autor:
Alexander Stein, Maurice Michel, Jens U. Marquardt, Helge Schroeder, Oliver Waidmann, Marcus-Alexander Woerns, Arndt Weinmann, Markus Moehler, Martin Maenz, Joseph Tintelnot, Friedrich Foerster, Joerg Trojan
Publikováno v:
Future Oncology. 17:3309-3319
Aim: To determine a recommended Phase II dose of the oral fluoropyrimidine trifluridine/tipiracil (FTD/TPI) combined with the multi-kinase inhibitor regorafenib (REG) in refractory metastatic colorectal cancer patients. Materials & methods: A convent
Autor:
Johannes Betge, Nadine Schulte, Sebastian Belle, Tianzuo Zhan, Beate Krammer-Steiner, Jean-Charles Moulin, Matthias Kleiß, Frank Lammert, Ulrich Wedding, Sebastian Räth, Martin Maenz, Lisa Hegele, Julian Larcher-Senn, Ralf Jesenofsky, Matthias P. Ebert, Nicolai Härtel
Publikováno v:
Journal of geriatric oncology. 13(5)
Older patients with metastatic pancreatic cancer may suffer increased toxicity from intensive chemotherapy. Treatment individualization by geriatric assessment (GA) might improve functional outcome.We performed a multicenter, phase IV, open label tri
Autor:
Anna Saborowski, Dirk Waldschmidt, Jan Hinrichs, Thomas Jens Ettrich, Uwe Marc Martens, Ardian Mekolli, Enrico N De Toni, Thomas Berg, Michael Geißler, Guido Hausner, Martin Maenz, Ursula Ehmer, Marta Kirstein, Arndt Vogel
Publikováno v:
Journal of Clinical Oncology. 40:4116-4116
4116 Background: Immunotherapy based combinations recently revolutionized the treatment of patients (pts) with advanced HCC, but its significance in earlier stages remains to be determined. TACE is commonly used as first line treatment in intermediat
Autor:
Matthias Philip Ebert, Nadja M Meindl-Beinker, Tobias Gutting, Martin Maenz, Johannes Betge, Nadine Schulte, Tianzuo Zhan, Philip Weidner, Ralf-Dieter Hofheinz, Arndt Vogel, Stefan Angermeier, Maike de Wit, Ralf Jakobs, Meinolf Karthaus, Gertraud Stocker, Peter C. Thuss-Patience, Tobias Leidig, Nicolai Haertel
Publikováno v:
Journal of Clinical Oncology. 40:303-303
303 Background: Overall survival of patients with advanced and refractory esophageal squamous cell carcinoma (ESCC) is poor. Most patients are 65 years or older, present with advanced and metastatic disease and suffer from extensive co-morbidity and
Autor:
Mike Thomas, Albrecht Stenzinger, Jonas Kuon, Johannes Krisam, Martin Maenz, Felix Lasitschka, Meinhard Kieser, Marc A. Schneider, Adriane Hommertgen, Farastuk Bozorgmehr, Miriam Blasi
Background: Elderly patients represent a major fraction of non-small cell lung cancer (NSCLC) patients in routine clinical practice, but they are still underrepresented in clinical trials. In particular, data regarding efficacy and safety in frail or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a58bf86246332585705d348fe4b239bb
https://doi.org/10.21203/rs.2.16770/v2
https://doi.org/10.21203/rs.2.16770/v2